Clotting Factors | AETNA Coverage Update

Summary: Aetna modified CPB 0131, its clotting factors coverage policy, effective April 24, 2026. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0131 governing clotting factor products. The policy covers hemophilia treatments and related clotting factor concentrates billed to Aetna plans. No specific CPT or HCPCS codes were published in the policy data available at the time of this writing — the CPB 0131 Aetna system document does not list individual codes directly. Review the full policy at the source before the effective date of April 24, 2026.

Quick-Reference Table

Aetna Clotting Factors Coverage Criteria and Medical Necessity Requirements 2026

CPB 0131 is Aetna's coverage policy for clotting factor products — the treatments at the center of hemophilia A, hemophilia B, and related bleeding disorder management. These products carry some of the highest per-claim costs in specialty billing. A policy modification here has real financial exposure for hematology practices, specialty pharmacies, and home infusion providers.

Aetna's clotting factors coverage policy historically requires documented medical necessity before covering factor concentrates. That means a confirmed diagnosis, documented bleeding episodes or prophylaxis rationale, and physician attestation of the treatment plan. Without that documentation in the claim file, you are looking at a claim denial.

Prior authorization is standard on clotting factor products across virtually all commercial payers — and Aetna is no exception. CPB 0131 ties reimbursement to prior auth approval, so a lapse in your auth tracking workflow is the fastest path to a denied claim on one of your highest-dollar line items. If your team manages factor billing across multiple Aetna plan types, confirm whether the April 24, 2026 modifications affect your specific plan population.

Because the full text of the updated CPB 0131 document was not included in the policy data available here, the precise criteria changes are not available in this post. Pull the updated document directly from Aetna's clinical policy library before April 24, 2026. If you manage significant clotting factor volume, talk to your compliance officer before the effective date.

Aetna Clotting Factors Exclusions and Non-Covered Indications

Clotting factor policies at major commercial payers — including Aetna — typically exclude coverage for several categories. These are the patterns to watch in CPB 0131.

Products used for conditions outside the approved diagnosis set are often excluded. This includes off-label use of recombinant factor products for non-hemophilia bleeding disorders when medical necessity criteria are not met.

Experimental or investigational factor products — those without FDA approval or sufficient clinical evidence — are typically not covered. New gene therapy products and novel clotting agents are areas where coverage policy lags behind clinical adoption. If your practice is administering newer agents, confirm their status under the updated CPB 0131 before billing.

Home infusion of clotting factors may carry specific documentation requirements distinct from outpatient or clinic-based infusion. Aetna's billing guidelines have historically required setting-specific documentation. Confirm whether the April 24, 2026 update changes any home infusion criteria.

Coverage Indications at a Glance

The policy data available for CPB 0131 does not include a published list of individual indications with coverage determinations. The table below reflects the general coverage framework for clotting factor policies of this type. Verify each row against the actual CPB 0131 document before April 24, 2026.

Note: This table reflects general policy patterns for clotting factor coverage policies. The CPB 0131 policy data provided did not include specific indication-level criteria. Treat this as a starting checklist, not a substitute for the actual policy document.

Aetna Clotting Factors Billing Guidelines and Action Items 2026

Clotting factor billing is high-stakes. These products generate some of the largest individual claim values in specialty billing — and coverage policy changes directly affect your reimbursement. Here is what your team should do before and after April 24, 2026.

CPT, HCPCS, and ICD-10 Codes for Clotting Factors Under CPB 0131

The CPB 0131 policy data provided for this post does not include a published list of specific CPT, HCPCS, or ICD-10 codes. This is not unusual — Aetna's clinical policy bulletins often reference codes within the full document rather than in summary data feeds.

Do not use this section as a substitute for the actual code list in the updated policy document. Pull the full CPB 0131 document directly from Aetna's clinical policy library to get the authoritative code set.

What to Look For in the Full Document

Clotting factor billing typically involves HCPCS J-codes for injectable clotting factor concentrates. These cover factor VIII products, factor IX products, and other recombinant or plasma-derived agents. The specific J-codes vary by product and formulation.

Diagnosis coding for clotting factor claims uses ICD-10-CM codes from the D66–D68 range, covering hereditary coagulation defects including hemophilia A, hemophilia B, and von Willebrand disease. Your ICD-10 codes must align with Aetna's covered diagnoses under the updated CPB 0131 — a mismatch is a direct route to claim denial.

Administration codes for infusion services — whether outpatient, clinic-based, or home infusion — are a separate billing layer. Confirm whether CPB 0131 addresses administration codes alongside the factor product codes.

Because no specific codes were published in the available policy data, this post cannot list them. Any code table here would be fabricated. Go to the source.